UY29149A1 - Tiazolil-dihidro-indazoles - Google Patents

Tiazolil-dihidro-indazoles

Info

Publication number
UY29149A1
UY29149A1 UY29149A UY29149A UY29149A1 UY 29149 A1 UY29149 A1 UY 29149A1 UY 29149 A UY29149 A UY 29149A UY 29149 A UY29149 A UY 29149A UY 29149 A1 UY29149 A1 UY 29149A1
Authority
UY
Uruguay
Prior art keywords
tiazolil
dihidro
indazoles
medication
excessive
Prior art date
Application number
UY29149A
Other languages
English (en)
Inventor
Dr Frank Hilberg
Dr Matthias Grauert
Christoph Hoenke
Dr Ulrike Weyer-Czernilofsky
Matthias Hoffmann
Steffen Breitfelder
Trixi Brandl
Bodo Betzemeier
Ralph Brueckner
Thomas Gerstberger
Michael Gmachl
Maria Impagnatiello
Dirk Kessler
Christian Klein
Bernd Krist
Udo Maier
Darryl Mcconnell
Charlotte Reither
Dr Stefan Scheuerer
Andreas Schoop
Norbert Schweifer
Oliver Simon
Martin Steegmaier
Steffen Steurer
Irene Waizenegger
Andreas Zoephel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004048877A external-priority patent/DE102004048877A1/de
Priority claimed from DE102005005813A external-priority patent/DE102005005813A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY29149A1 publication Critical patent/UY29149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La presente invención incluye compuestos de fórmula general (1) donde R1 a R3 están definidos como en la reivindicación 1, que son adecuados para el tratamiento de enfermedades que se caracterizan por proliferación celular excesiva o normal, así como su uso para la preparación de un medicamento con las propiedades que se indicaron precedentemente.
UY29149A 2004-10-07 2005-10-04 Tiazolil-dihidro-indazoles UY29149A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004048877A DE102004048877A1 (de) 2004-10-07 2004-10-07 PI3-Kinasen
DE102005005813A DE102005005813A1 (de) 2005-02-09 2005-02-09 PI3-Kinasen
EP05107230 2005-08-05

Publications (1)

Publication Number Publication Date
UY29149A1 true UY29149A1 (es) 2006-05-31

Family

ID=35448324

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29149A UY29149A1 (es) 2004-10-07 2005-10-04 Tiazolil-dihidro-indazoles

Country Status (23)

Country Link
EP (1) EP1799690B1 (es)
JP (1) JP5090914B2 (es)
KR (1) KR20070113188A (es)
CN (1) CN101035795B (es)
AR (1) AR051743A1 (es)
AT (1) ATE392425T1 (es)
AU (1) AU2005293609B2 (es)
BR (1) BRPI0518169A (es)
CA (1) CA2579288A1 (es)
CY (1) CY1108183T1 (es)
DE (1) DE502005003777D1 (es)
DK (1) DK1799690T3 (es)
ES (1) ES2304022T3 (es)
IL (1) IL182397A (es)
MX (1) MX2007003802A (es)
NZ (1) NZ554695A (es)
PE (1) PE20060583A1 (es)
PL (1) PL1799690T3 (es)
PT (1) PT1799690E (es)
SI (1) SI1799690T1 (es)
TW (1) TW200630374A (es)
UY (1) UY29149A1 (es)
WO (1) WO2006040281A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
BRPI0710843A2 (pt) * 2006-04-06 2011-08-23 Boehringer Ingelheim Int tiazolil-di-hidro-indazóis
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
BRPI0710841A2 (pt) * 2006-04-06 2011-08-23 Boehringer Ingelheim Int compostos derivados de tiazolil dihidroindazóis como inibidores da proteìna quinase, preparações farmacêuticas e o uso das mesmas
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
PE20080371A1 (es) 2006-05-19 2008-04-09 Wyeth Corp N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3
EP2045253A4 (en) * 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
PE20091617A1 (es) * 2008-03-13 2009-11-12 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
KR20100122513A (ko) * 2008-07-17 2010-11-22 아사히 가세이 파마 가부시키가이샤 질소 함유 복소환 화합물
JP5579724B2 (ja) 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
US8288379B2 (en) * 2009-04-22 2012-10-16 Boehringer Ingelheim International Gmbh Thia-triaza-cyclopentazulenes
JP5901020B2 (ja) * 2009-04-22 2016-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療用ＰＩ３−キナーゼ阻害薬としてのチア−トリアザ−ａｓ−インダセン
EA201200087A1 (ru) 2009-07-02 2012-07-30 Новартис Аг 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
EP2723733A1 (en) * 2011-06-21 2014-04-30 Novartis AG Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
JP2022544583A (ja) * 2019-08-16 2022-10-19 サイクラセル リミテッド ピリミジノ－ジアゼピン誘導体の調製のための方法
CN112876503B (zh) * 2021-03-18 2022-04-29 中国科学院兰州化学物理研究所 用于癌症硼中子俘获治疗药物的硼酸盐化合物及其制备

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
WO2003035618A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Also Published As

Publication number Publication date
CA2579288A1 (en) 2006-04-20
MX2007003802A (es) 2007-04-23
SI1799690T1 (sl) 2008-08-31
EP1799690B1 (de) 2008-04-16
CN101035795B (zh) 2012-03-21
CN101035795A (zh) 2007-09-12
JP5090914B2 (ja) 2012-12-05
PL1799690T3 (pl) 2008-09-30
AR051743A1 (es) 2007-02-07
PT1799690E (pt) 2008-06-16
DK1799690T3 (da) 2008-06-30
ES2304022T3 (es) 2008-09-01
AU2005293609A1 (en) 2006-04-20
WO2006040281A1 (de) 2006-04-20
CY1108183T1 (el) 2014-02-12
BRPI0518169A (pt) 2008-11-04
TW200630374A (en) 2006-09-01
NZ554695A (en) 2010-12-24
IL182397A (en) 2011-11-30
EP1799690A1 (de) 2007-06-27
IL182397A0 (en) 2007-07-24
JP2008515854A (ja) 2008-05-15
PE20060583A1 (es) 2006-08-17
ATE392425T1 (de) 2008-05-15
AU2005293609B2 (en) 2011-11-24
DE502005003777D1 (de) 2008-05-29
KR20070113188A (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
UY29149A1 (es) Tiazolil-dihidro-indazoles
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ECSP088932A (es) Nuevos compuestos químicos
ECSP099823A (es) Nuevos compuestos químicos
ECSP088905A (es) Nuevos compuestos
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
ECSP11010786A (es) 5-alquinil-pirimidinas
CO6640285A2 (es) 5-alquinil-pirimidinas
AR047529A1 (es) Compuestos de quinolina sustituidos
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
ECSP12011830A (es) Nuevos compuestos.
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
HN2009000784A (es) Dihidropirazolonas sustituidas
ECSP11010816A (es) Nuevos Compuestos
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP099806A (es) Oxazolidinonas sustituidas y su uso
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160601